Clobazam Versus Placebo for Anxiety and Tension in Psychoneurotic Outpatients. A Multicenter Collaborative Study

Publisher Website
Google Scholar
Abstract
Clobazam, a 1,5-benzodiazepine, was compared with placebo in 190 psychoneurotic outpatients with prominent symptoms of anxiety and tension of at least 2 wk duration. The design was one of double-blind parallel groups treated for 1 wk. Clobazam subjects began on 40 mg daily in divided dosage, which was increased to 80 mg daily by day 3 if the drug was well tolerated. Two patients receiving clobazam had laboratory chemistry abnormalities which were possibly drug related. Adverse effects occurred more frequently in the clobazam group and were typical of those of marketed benzodiazepines. This study indicates that clobazam is an effective anxiolytic agent demonstrating its clinical effects during the 1st wk of treatment.